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Certain members of the microbiota genus Bifidobacterium are known to
positively influence host well-being. Importantly, reduced bifidobacterial
levels are associated with inflammatory bowel disease (IBD) patients, who
also have impaired epithelial barrier function, including elevated rates of apop-
totic extrusion of small intestinal epithelial cells (IECs) from villi—a process
termed ‘cell shedding’. Using a mouse model of pathological cell shedding,
we show that mice receiving Bifidobacterium breve UCC2003 exhibit significan-
tly reduced rates of small IEC shedding. Bifidobacterial-induced protection
appears to be mediated by a specific bifidobacterial surface exopolysaccharide
and interactions with host MyD88 resulting in downregulation of intrinsic
and extrinsic apoptotic responses to protect epithelial cells under highly
inflammatory conditions. Our results reveal an important and previously
undescribed role for B. breve, in positively modulating epithelial cell shedding
outcomes via bacterial- and host-dependent factors, supporting the notion that
manipulation of the microbiota affects intestinal disease outcomes.1. Introduction
Bifidobacteria represent one of the first colonizers of the infant gut and are promi-
nentmembers of the adult gutmicrobiota [1,2]. They have been linked to a number
of health-promoting activities, including the promotion of anti-tumour immunity
[3], modulation of antimicrobial activities against pathogenic bacteria [4] and pro-
tection against relapse of ulcerative colitis [5,6]. Despite these purported benefits,
the molecular mechanisms underlying these protective effects by bifidobacteria
remain largely unknown, although recently components of their surface, including
the exopolysaccharide (EPS), have been shown to play a significant role in modu-
lating protective effects [7]. It is critical to obtain detailed insights into the mode of
action by which microbiota members sustain and improve host health, as this will
be central to future disease treatment/prevention strategies.
There is a growing body of evidence suggesting that the microbiota influ-
ences intestinal epithelial cell (IEC) function, including gene expression, cell
division and energy balance [8–11]. These symbiotic bacterial/host relation-
ships have co-evolved to the extent that the microbiota is indispensable for
the maintenance of gut homeostasis [12]. Importantly, microbial dysbiosis, as
indicated by a reduction in overall diversity, including specific reductions in
Bifidobacterium, has been linked to inflammatory bowel disease (IBD) [13–15],
underlining the critical importance of host/microbe interactions in maintaining
a steady state within the intestine.
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line of defence against entry of bacteria into host tissues.
Cell division in the crypt, under physiological conditions, is
counterbalanced by cell shedding from the villi to maintain
homeostasis and integrity of the crypt/villus axis. When the
epithelial cell is shed, a discontinuity in the villus epithelial
monolayer is created, which potentially compromises the
epithelial barrier. In health, epithelial barrier function is main-
tained [16], owing to a dramatic redistribution of apical
junction complex proteins, including zonula occludin 1 (ZO-
1), occludin 1 and E-cadherin, which form a funnel that sur-
rounds the shedding cell and plugs the resulting gap until the
movement of neighbouring epithelial cells restores epithelial
continuity [17–19].
TNF-a is a key cytokine in IBD. We and others have shown
that TNF-a induces apoptosis of villus tip epithelial cells caus-
ing excessive shedding, leading to breakdown of the epithelial
barrier andmicroulceration [16,20]. Delayed repair of epithelial
defects caused by excessive cell shedding contributes to the
development of macroscopic ulceration [21]. Our studies
with confocal endomicroscopy of patients with IBD in clinical
remission have demonstrated that those patients with high
rates of cell shedding are more likely to relapse than those
with low shedding rates, demonstrating a causative link
between barrier function and the inflammatory response [21].
Given reports of beneficial effects of certain members of
the gut microbiota in IBD and potential roles of microbial
dysbiosis in these diseases, we hypothesized that certain health-
promoting microbiota members, including Bifidobacterium,
may play a role in protecting against the cell shedding response
by modulating IEC function. To determine the contribution of
bifidobacteria in cell shedding, we employed a well character-
ized in vivomousemodel inwhich pathological cell shedding is
induced by intraperitoneal (IP) administration of lipopoly-
saccharide (LPS), driving mononuclear cell expression of
TNF-a and subsequent caspase-3-positive shedding cells [22].
Our results suggest a particular bifidobacterial strain (i.e.
human isolate B. breve UCC2003) positively modulates the
small intestinal cell shedding response via host MyD88- and
bacterial EPS-dependent interactionswhich serve to significan-
tly reduce apoptotic signalling in the epithelial compartment.
These data identify a previously unknown mechanism by
which Bifidobacterium protects its host against pathological
cell shedding. These findings may thus have important impli-
cations for the future design of therapeutic strategies in the
context of intestinal diseases.2. Material and methods
2.1. Animals
C57 BL/6 Jax mice (6–10 weeks) were obtained from Charles
River. Vil-cre MyD88 transgenic mice (i.e. Cre recombinase
expression causes truncation and resulting non-function of
the MyD88 protein in IECs) were obtained from the Wellcome
Trust Sanger Institute (kind gift from S. Clare).
2.2. Bacterial culture and inoculations
Bifidobacterium breve strains UCC2003, UCC2003del and
UCC2003inv were used for animal inoculations. These strains
and corresponding culturing conditions have been previouslydescribed in detail [7]. In brief, colonies were established
from frozen glycerol stocks onto reinforced clostridial agar
(RCA) plates before being subcultured into reinforced clostri-
dial medium and subsequently Man Rogosa Sharpe medium
(Oxoid, Hampshire) under anaerobic conditions. Bacteria
were then purified by centrifugation and washed in PBS con-
taining L-cysteine before being reconstituted in sterile PBS at a
final concentration of approximately 1  1010 bacteria ml21.
0.1 ml of inoculum was then administered to mice by oral
gavage in 3  24 h doses followed by plating of faecal pellets
on RCA containing 50 mg l21 mupirocin to confirm stable
colonization. Control mice received oral gavage of PBS only.
2.3. Lipopolysaccharide injections and tissue collections
Twenty-four hours after the last doses of B. breve or PBS con-
trol, mice received an IP injection of 1.25 mg kg21 LPS from
Escherichia coli 0111:B4 (Sigma) or sterile saline (control)
and mice were sacrificed 1.5 h post-challenge with LPS. Prox-
imal small intestine was collected in 10% neutral buffered
formalin saline (Sigma) and fixed for 24 h followed by paraf-
fin embedding. Samples of proximal small intestine were also
collected into RNA Later (Qiagen) for transcriptome analysis
or frozen on dry ice for subsequent ELISA analysis. In some
cases, proximal small intestine was also collected into Hanks
buffered saline solution (HBSS) for isolation of IECs.
2.4. Immunohistochemistry
Sections (5 mm) of paraffin-embedded small intestinal tissue
were sectioned and used for immunohistochemistry. Follow-
ing de-parafinization and rehydration, tissue sections were
treated with 1% hydrogen peroxide in methanol to block
endogenous peroxidases. Subsequently, slides were treated
using heat-induced antigen retrieval in 0.01 M citrate acid
buffer (pH 6) followed by incubation with a rabbit polyclonal
anti-active caspase-3 (CC3) antibody (AF835: R&D Systems).
Visualization of caspase-3 positivity was via a peroxidase-
labelled anti-rabbit EnVision secondary antibody (Dako) and
3,30-diaminobenzidine followed by counterstaining with
haematoxylin. For macrophage staining, an antibody against
F4/80 antigen (ab6640: Abcam) was employed using biotiny-
lated anti-rat (BA-9401) and avidin–biotin reagent (PK-6100;
Vector Laboratories).
2.5. Quantification of caspase-3 positivity
IECs were counted on a cell positional basis from villus tip (cell
position (CP) 1) down towards the crypts under 400 magnifi-
cation. Twenty well-orientated hemi-villi were counted per
mouse and analysed using the SCORE, WINCRYPTS [23] and
PRISM analysis software. IECs were defined as ‘normal’ in
cases where staining for active caspase-3 was absent. Immuno-
labelled cells with either unaltered or shedding morphology
were treated as caspase-3 positive. Imaging was performed
with anOlympusBX60microscope andC10plus digital camera.
2.6. RNA isolation and real-time polymerase chain
reaction
Samples fixed in RNAlater solution were processed through
RNeasy plus mini spin columns to isolate total RNA (Qiagen).
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held homogenizer in buffer RLT before processing through a
QIAshredder column and subsequently RNeasy mini-spin col-
umns. Purified RNA was eluted into RNAase free water.
Reverse transcription was performed using the Quantitect
reverse transcription kit (Qiagen) and cDNA used for real-
time (RT-)PCRanalysis. ForRT-PCR, transcriptswere amplified
using Quantifast SYBR green mastermix (Qiagen) and Quanti-
tect primer assays for TNF-a, TNF-R1 and F4/80 (EMR1).
Expression of the housekeeping gene hypoxanthine–guanine
phosphoribosyltransferase (HPRT) 50-GACCAGTCAACAG
GGGACAT-30 (sense) and 50-AGGTTTCTACCAGTTCCAGC-
30 (antisense) [24] was also determined. Cycling was performed
on a Roche LightCycler 480 using the following conditions:
958C, 5 min then 40 cycles of 958C, 10 s; 608C, 35 s. Relative
quantification of levels of transcript expression was calculated
using the Pfaffl method [25] by comparing cycle threshold
(CT) value of each target gene to the CT value of housekeeper.
Data are presented as a ‘fold change’ in expression (normalized
against control untreated mice per cells).
2.7. Isolation of intestinal epithelial cells and FACS
analysis
IECs were isolated using a modification of the Weiser method-
ology [26]. In brief, whole small intestine was collected in
ice-cold HBSS before being chopped into 0.5 cm2 pieces and
washed in a solution containing 0.154 M NaCl and 1 mM
DTT, and subsequently a solution containing 1.5 mM KCl,
96 mM NaCl, 27 mM tri-sodium citrate, 8 mM NaH2PO4 and
5.6 mM Na2HPO4, pH 7.3. IECs were then isolated by incu-
bation in PBS containing 1.5 mM EDTA and 0.5 mM DTT,
shaking at 200 r.p.m. and at 378C. Purity of epithelial prep-
arations was confirmed by histological analysis of stripped
intestinal mucosa and by FACS analysis of isolated cells. For
FACS analysis, 5  106 cells were stained with anti-mouse
CD45-A700 (Biolegend) on ice for 30 min. After two washes
in HBSS containing 0.01 BSA, 2 mM EDTA, 20 mM HEPES
and 0.01% NaN3, propidium iodide was added (Biolegend)
and samples analysed on a Sony FCS SH-800 flow cytometer.
Data were analysed using FLOWJO (TreeStar).
2.8. ELISA
Frozen proximal small intestinal samples were homogenized
in extraction buffer containing protease inhibitors (Roche),
cleared by centrifugation and analysed using a commercial
ELISA kit for TNF-a (eBioscience) as per manufacturer’s
protocol. Measurement of TNF-a immunoreactivity was at
450 nm, using a Fluostar Optima plate reader (BMG Labtech).
2.9. SDS–PAGE and Western blotting
Isolated IECs were lysed in CelLytic MT reagent (Sigma)
before centrifugation at 10 000 rpm for 10 min to pellet cellular
debris. Supernatants were mixed with 2  Laemmli sample
buffer before being separated by sodium dodecyl sulfate
(SDS)–PAGE with 3–14% acrylamide gel and transferred to
Hybond-PPVDFmembrane (GEHealthcare, Buckinghamshire,
UK) and blocking with 5% Marvel milk in with tris(hydroxy-
methyl)aminomethane (Tris). (Tris)-buffered saline containing
Tween 20 (TTBS) immunostaining was performed with 1/1000 anti-TNF-R1 antibody (Abcam) and 1/5000 goat anti-
Rabbit IgG HRP conjugate (Millipore) on a reduced gel.
Macrophage expression was analysed similarly using antibody
against F4/80 antigen (Abcam) at 1 : 1000 and goat anti-rat
IgG-HRP (SantaCruz, at 1 : 3000), on a non-reduced gel.
Washes were in TTBS. For detection, Immobilon Western
chemiluminescent HRP substrate (Millipore) was applied to
the membrane as recommended by the manufacturer and
signal was detected, using a FluorChem E imaging system
(Protein Simple). Band densities were quantified using FIJI [27].
2.10. Polymerase chain reaction array analysis
Real-rime ready Custom Panel 480–96þ PCR arrays were
obtained (Roche) and quantitative PCR analysis performed.
RNA was extracted from whole small intestinal tissue pre-
served in RNAlater reagent (Sigma), using RNeasy plus
mini kits (Qiagen). Reverse transcription was performed,
using Transcriptor First Strand cDNA Synthesis Kit followed
by analysis of targets using LightCycler 480 Probes Master on
a LightCycler 480 platform (all Roche). Standard protocols as
per manufacturer recommendations were followed. CT
values of target genes were normalized to expression of the
housekeeping gene HPRT and fold change versus control
samples calculated using the delta/delta CT method [25].
2.11. Statistical analysis
Experimental results were plotted and analysed for statistical
significance with PRISM v. 5 software (GraphPad Software).
A p-value of less than 0.05 was used as significant in all cases.3. Results
3.1. Lipopolysaccharide induces cell shedding from
small intestinal villi in a dose-dependent manner
Caspase-3 is activated in IECs during their extrusion from the
tips of small intestinal villi [18,28]. Similar to previous
reports, we found that control C57 BL/6 mice receiving IP
PBS injection showed low levels of cell shedding as evi-
denced by low level expression of cleaved caspase-3 (CC3)
in the epithelial cell layer (figure 1a). Recent studies have
demonstrated that following IP injection of mice with LPS
isolated from Escherichia coli 0111:B4, a potent cell shedding
response is induced, similar to that observed in relapsing
IBD patients [22]. In agreement with these studies, we
found a significant increase in CC3-mediated cell shedding
at 1.5 h post-injection of 1.25 mg kg21 LPS, not only at the
villus tip, but also along the shoulders and sides of the
villus (figure 1b). Effects of LPS on the cell shedding response
were found to be dose-dependent, in agreement with
previous observations [22] (data not shown).
3.2. Bifidobacterium breve modulates
lipopolysaccharide-induced cell shedding
Various members of the microbiota are known to promote a
healthy gut [29], although the precise mechanisms behind
this remain incompletely understood. We reasoned that
because the integrity of the intestinal epithelium is intrinsically
(b)(a)
Figure 1. LPS challenge induces cell shedding from small intestinal villi. C57 BL/6 mice were administered either (a) PBS (control) or (b) LPS by IP injection and
proximal small intestines removed after 1.5 h. Processed tissue was sectioned and stained by immunohistochemistry for CC3 (i.e. brown cells indicate shedding
event), also highlighted by arrows. A representative picture for each group is shown (12 mice per group, two independent experiments).
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Figure 2. Bifidobacterium breve UCC2003 protects against LPS-induced cell shedding. C57 BL/6 mice received three daily oral gavage doses of (a) PBS or (b)
approximately 1  109 B. breve UCC2003 followed by IP challenge with LPS 24 h later. Representative images are shown. Formalin-fixed, paraffin-embedded intes-
tinal sections were sectioned and stained with anti-CC3 and (c) quantified using the WINCRYPTS and SCORE programs, 20 well-orientated hemi-villi were counted per
mouse. Data are mean+ s.d., n ¼ 12 (two independent experiments) analysed with a Mann–Whitney U-test.
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is expected to impact on epithelial cross-talk, such health-
promoting species might play a role in regulating cell
shedding. To test this, groups of C57 BL/6 mice were initially
dosed with vehicle control (PBS) or with 1  109 B. breve
UCC2003 (isolated from a healthy infant) in 3  24 h doses
orally to establish stable colonization [7]. Colonization was
confirmed by faecal CFU counts on day 4 (electronic sup-
plementary material, figure S1). Mice were then administered
LPS to induce pathological cell shedding, followed by sacrifice
at 1.5 h. Following dosingwith B. breveUCC2003 and inductionof cell shedding with LPS, mice showed a marked reduction in
the levels of CC3-positive shedding cells compared with LPS-
treated control mice receiving PBS gavage (figure 2a,b). Cell
count analysis confirmed significant reduction (p, 0.01) in
cell shedding at the majority of positions along the length of
the villus in B. breve UCC2003-treated mice (figure 2c). Thus,
B. breve appears to modulate epithelial integrity/survival
during periods of inflammatory insult.
Previous studies have indicated that bifidobacteria may
modulate the composition of other microbiota members,
and within the context of IBD, studies have linked
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if bifidobacterial colonization impacts the gut microbiota, we
analysed the community composition using a 16S rRNA-
based sequencing approach. We found minor changes to
the community structure in B. breve UCC2003 versus control
treated mice (C57 BL/6), but overall, no notable differences
(but expected increase in Actinobacteria in the B. breve
UCC2003 group) in microbiota class abundance between the
treatment groups (electronic supplementary material, figure
S2). Bifidobacterial colonization takes place along the gastroin-
testinal (GI) tract including the small/large intestine and
caecum. RNAscope analysis showed that B. breve UCC2003
was found in intimate contact with the IECs of the small intes-
tine in colonized C57 BL/6 mice (electronic supplementary
material, figure S3). Together, these data suggest that coloniza-
tion with B. breve does not produce significant shifts in the
overall gut microbiota community structure and that the
observed protective effects after colonization are more likely
to be related to direct effects of B. breve, possibly through
interactions with the IECs.3.3. The mechanism of protection against
lipopolysaccharide-induced cell shedding is TNF-a
independent
LPS-induced cell shedding is caused by the release of TNF-a
from lamina propria tissue-resident macrophages, which
binds to TNF-receptor 1 (TNF-R1), on IECs [22], thereby driv-
ing the apoptotic response. Conditioning of macrophage
responses by the microbiota has been reported previously
[30] and, consistent with these data, bacteria such as B. breve
have been described to possess immunomodulatory properties
[31]. Thus, to determinewhether the cell shedding outcome, as
modulated by B. breve, was caused by reduced expression of
TNF-a from macrophages, we isolated RNA and protein
from whole small intestine of control and B. breve UCC2003-
treated C57 BL/6 mice following LPS-mediated induction of
cell shedding. As shown in figure 3a, no significant difference
( p. 0.05) in levels of TNF-a protein was observed bet-
ween groups, and this was confirmed at the transcriptional
level (data not shown). We also found no significant changes
( p. 0.05) in expression of TNF-a in the plasma of B. breve
UCC2003-treated versus control mice following LPS-induced
cell shedding (figure 3b), nor any significant difference ( p.
0.05) in the numbers/levels of F4/80þmacrophages infiltrating
the small intestine (figure 3c–f). Together, these data suggest
that modulation of the reduced cell shedding response is inde-
pendent of TNF-a induction. Because the microbiota may be
able to interact directly with IECs, we postulated that B. breve
modulates a signalling pathway downstream of the TNF-a
ligand. To test whether expression of TNF-R1 was altered in
the epithelium following dosing with B. breve UCC2003, IECs
were isolated from whole small intestinal tissue using a modi-
fied Weiser methodology [32], after which purity of the IEC
population was confirmed by histological analysis of stripped
intestinal tissue and FACS analysis (figure 3g,h). Subsequent
quantitative RT-PCR and western blot analysis of isolated
IEC populations showed no significant changes ( p. 0.05) to
expression of the TNF-R1 transcript or protein following
exposure to B. breve UCC2003 (figure 3i–k), suggesting that
there is no impairment of signalling at the level of the receptor.3.4. Functional epithelial MyD88 signalling is required
for Bifidobacterium breve-mediated protection
against cell shedding
IECs sample microbe-associated molecular patterns (MAMPS)
of the intestinal luminal contents using a variety of receptors
including members of the nucleotide-binding oligomerization
domain (NOD) family, the C-type lectin receptor (CLR) family
and the Toll-like receptor (TLR) superfamily. MyD88 is a criti-
cal adaptor protein in signalling downstream of the majority
of the TLR family members [33]. We thus used epithelial-
specific (Vil-Cre) MyD88 knockout mice to determine
whether B. breve elicits its protective effects via epithelial TLR
signalling pathways.
C57 BL/6 MyD882/2 villin-cre mice (i.e. IEC MyD88 KO
mice) colonized with B. breve UCC2003, showed similar rates
(p. 0.05) of LPS-induced cell shedding to PBS gavaged IEC
MyD882/2 mice. In comparison, control mice (i.e. C57 BL/6
MyD88þ/þ villin-cre) showed the expected protection (p,
0.01) against cell shedding in the presence of B. breve UCC2003
(figure 4a–d). Furthermore, RT-PCR analysis of IEC homogen-
ates showed increased expression (p, 0.001) of TLR2 in
B. breve UCC2003-colonized mice when compared with control
mice (i.e. PBS, figure 4e). Taken together, these data indicate
that functional MyD88 signalling, potentially via TLR2 is
required for modulating the protective effect of B. breve against
cell shedding outcomes.
3.5. Bifidobacterium breve exopolysaccharide plays a
role in modulating protection against
lipopolysaccharide-induced cell shedding
Recently, a number of functions modulated by bifidobacteria
have been shown to be mediated through surface-associated
EPS including resistance to gut infection [7]. Interestingly,
the eps gene clusters represent a relatively conserved feature
of bifidobacterial genomes, including those of the species B.
breve [34]. In order to investigate the role of EPS in modulat-
ing the response against cell shedding, we used a deletion
mutant (B. breve UCC2003-EPSdel) that expresses neither
EPS1 nor EPS2 [7]. Mice were stably colonized by dosing
with B. breve EPS-positive or EPS-negative strains followed
by challenge with LPS (electronic supplementary material,
figure S1). Strikingly, when colonized with the B. breve
UCC2003-EPSdel, no significant protection ( p. 0.05) against
cell shedding was observed in control (i.e. PBS) versus
colonized mice (figure 5a,b).
Bifidobacterium breveUCC2003 controls EPS biosynthesis via
a bidirectional gene cluster which results in expression of either
EPS1 (B. breveUCC2003) or EPS2 (B. breveUCC2003-EPSInv) [7].
Thus, togain further insights into the roleof adifferentEPS in the
protective cell shedding response, we undertook studies using
B. breve UCC2003-EPSInv. Colonization with EPS2 expressing
B. breve (i.e. B. breve UCC2003-EPSInv) also failed to show any
significant protection (p. 0.05) against LPS-induced cell shed-
ding, suggesting considerable variation in the protective
response dependent upon EPS genetic and chemical structure
and organization (figure 5c,d). All strains are directly compared
in electronic supplementary material, figure S4.
Together, these studies emphasize the striking strain var-
iant specificity that is observed with regard to the individual
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shedding. This is probably regulated by the specific molecules
produced by each strain, including the EPS. This highlights the
critical need to fully genetically characterize ‘probiotic’ strains
of bacteria to enable a detailed dissection of their functional
effects in vivo for optimal translation to human patients.3.6. Bifidobacterium breve exopolysaccharide attenuates
inflammatory and apoptosis signalling
In order to gain further insights into the changes taking place
in the small intestine following colonization with B. breve
UCC2003 and the influence of EPS, whole small intestinal
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B. breve UCC2003 and EPS-negative B. breve UCC2003-del)
mice following challenge with LPS were analysed using a
custom RT-PCR array (figure 6: 49/84 targets are shown;
full set of data is displayed in electronic supplementarymaterial, figure S5) to look for transcriptional changes to
key inflammatory transcripts and those involved in the
apoptotic cascade. Interestingly, small intestinal samples
from B. breve UCC2003-EPSdel-colonized mice (figure 6a;
electronic supplementary material, figure S5a,b) showed
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and Tnfrs15 when compared with control and LPS-chal-
lenged mice. Moreover, numerous other apoptotic and
inflammatory genes were significantly upregulated (more
than twofold, p, 0.01) including Bad, Cycs (cytochrome c,
Somatic), casp4, Fas, Traf5 and Tnfrs9. In contrast, in EPS-
positive-colonized mice (i.e. B. breve UCC2003), our analysis
showed only subtle changes to the expression of the majority
of the targets when compared with PBS-treated control mice
challenged with LPS (figure 6b; electronic supplementary
material, figure S5c,d ). In addition, while significant elevation
(more than twofold and p, 0.05) in IL-6 and Tnfrs15 was
observed following colonization with B. breve UCC2003,
Tnfrs15 expression was markedly decreased versus B. breve
UCC2003-EPSdel-colonized mice (threefold versus 16-fold
increase). These data suggest that signalling via EPS may
downregulate inflammatory and apoptotic networks, which
would otherwise lead to elevated cell shedding.4. Discussion
We report that colonization of mice with B. breve significan-
tly reduces pathological/apoptotic epithelial cell shedding,through a previously unknown mechanism involving
bifidobacterial EPS-MyD88 signalling.
The gut microbiota appears central to maintaining epi-
thelial barrier integrity and, importantly, disturbances in the
microbiota appear pivotal in IBD pathogenesis. Indeed, IBD
patients (paediatric and adult cohorts) have been shown to
possess a reduced overall microbiota diversity and reduc-
tions in specific genera including Clostridium, Bacteroides,
Faecalibacterium and (of particular interest here) Bifidobacterium
[6,15,35]. Previous clinical trials have shown that adminis-
tration of bifidobacterial strains can reduce the incidence of
relapse in patients suffering from IBD [36]. Following LPS-
induced cell shedding, we observed that a priori administration
of B. breve UCC2003 (which is a human-isolated strain, thus
more translationally relevant) conferred a significant level of
protection, which manifested as significantly reduced cas-
pase-3 positivity within the villus epithelium (figure 2a–c).
Previous studies have highlighted that bifidobacterial
supplementation may also modulate the wider microbiota
in mouse models [37]. However, our data indicate that
while there are modest differences between PBS and
B. breve-colonized mice (as indicated by taxa abundance),
there are no notable differences (with high variability
between animals), suggesting limited effects on overall micro-
biota profiles (electronic supplementary material, figure S2).
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dobacteria and maintenance of epithelial integrity in the
prevention of intestinal inflammation.
Previous studies have indicated that Bifidobacterium pre-
dominantly colonizes the colon of infants and adults, as
determined from faecal or mucosal scrapings, or biopsy
samples [38,39]; however, in this work (using a murine
model), we have described SI-specific responses. From a
translational perspective, in humans, these protective cell
shedding responses may result from bifidobacteria cross-
talk in the lower SI. Although difficult to measure in
humans, previous studies have indicated Bifidobacterium colo-
nization in the lower SI (i.e. the ileum, as we observe in our
model). Notably, select studies using ileostomy effluents
and illeum biopsies have indicated bifidobacteria (specifically
B. animalis subsp. lactis and B. breve, respectively) are present
in this area of the infant and adult GI tract [40,41]. Therefore,
in the human context, we may observe direct SI signalling via
resident bifidobacteria and/or remote SI feedback signalling
from colonic bifidobacteria epithelium cross-talk, which
could be tested in future clinical intervention studies.
As previously mentioned, studies have shown that this
experimental model of LPS-induced cell shedding is driven
by an induction in expression of TNF-a from the intestinal
mucosa [22,42]. One of the key functions of the gut microbiota
is induction of tolerogenic or anti-inflammatory immune
responses and thus we hypothesized that bifidobacteria may
reduce cell shedding as a direct result of inhibiting TNF-a
and macrophages—a potential source of TNF. However, we
were unable to detect any changes in levels of TNF-a expression
or macrophage infiltration from B. breve UCC2003-treated or
control (i.e. PBS) mice (figure 3a–f), suggesting that the protec-
tion conferred by Bifidobacterium strains is TNF-a independent.
Previous studies have indicated that colonization of B. breve
UCC2003 during homeostatic conditions does not induce
differences in splenic TNF-a-positive macrophage numbers
when compared with non-colonized controls [7]. Coupled
with the lack of change in expression in TNF-R1 following colo-
nization (figure 3i–k), it appears that macrophages, TNF-a
production and TNF-R1 signalling are not involved inmodulat-
ing this protective response and suggests that B. breveUCC2003
acts preferentially from the luminal side through interactions
with IECs.We cannot exclude the potential for EPS to block sig-
nalling via TNF-R1.However, TNF-R1 expression appears to be
restricted to the basolateral surface of epithelial cells and thus
B. brevewould not be expected to have direct access to this cel-
lular compartment for direct inhibition via binding [43].
Furthermore, quantification of downstream effectors (electronic
supplementary material, figure S5) including FADD, TRAF2
and caspase 2 and 8 does not significantly differ between
B. breve UCC2003 and B. breve UCC2003-del-colonized mice,
which suggests EPS does not play a key role via TNF-R1.
To delineate these protective luminal bifidobacterial–
epithelial interactions, we used epithelial-specific MyD88 KO
mice; MyD88 is a key adaptor protein downstream of
microbe-TLR signalling. Notably, mice carrying truncated epi-
thelial MyD88 (i.e. C57 BL/6MyD882/2 villin-cre) showed no
protection against cell shedding after colonization of B. breve
UCC2003 (figure 4c,d); this was in stark contrast to MyD88-
positive control animals, which again showed significant
protection against LPS-induced cell shedding (figure 4a,b).
Furthermore, we observed significant increases in IEC TLR2
expression in B. breve UCC2003-colonized mice (figure 4e).Interestingly, previous work has indicated that TLR2 may
enhance ZO-1 associated intestinal epithelial barrier integrity
[44], and other studies indicate that mice deficient in MyD88
signalling have increased susceptibility to intestinal inflam-
mation [12]. In a UV model of apoptosis, MyD88 signalling
appears to reduce caspase-3 and in turn increase cell survival,
andmore recentlyB. bifidumhasbeen shown to reduce apoptosis
in vitro (necrotizing enterocolitis IEC-6 cell model), as also indi-
cated by reduced CC3-positive cells [45]. Thus, our data, in
tandem with these studies, indicate that B. breve UCC2003 may
regulate epithelial integrity in response to LPS-induced cell
shedding (as marked by caspase-3) via these central MyD88
signalling mechanisms, potentially downstream of TLR2.
Having determined the importance of host adaptor
MyD88, we next sought to determine if there was a specific
bifidobacterial molecule central to the observed protective
response. Because we have previously shown that surface
EPS of B. breve UCC2003 can regulate the host response [7],
we investigated the ability of an EPS mutant B. breve
UCC2003-EPSdel (complete deletion of eps biosynthetic clus-
ter) to modulate LPS-induced cell shedding. Notably, mice
receiving B. breve UCC2003-EPSdel showed no significant
protection against cell shedding when compared with EPS-
positive (i.e. B. breve UCC2003) colonized mice (figure 5a,b),
suggesting an important role for this EPS in microbe–host
cross-talk. Importantly, EPS structures can be recognized via
TLR2 (and signal via MyD88), and previous work with the
polysaccharide A (PSA) capsule of Bacteroides fragilis highlights
that PSA canmodulate dendritic cell andT regulatory cell func-
tion via TLR2 signalling [46,47]. Additionally, previous work
has highlighted that a strain of B. breve (Yakult strain) can
also induce IL-10 producing T regulatory cells via TLR2; how-
ever they did not determine if this was via an EPS-specific
mechanisms [48]. Furthermore, recent studies using Bacillus
subtilis have demonstrated that the EPS capsule of this bacter-
ium is able to protect against intestinal inflammation in a
murine model of colitis (in this instance via TLR4), providing
further support for the likely role of bifidobacterial EPS in the
effects observed in these studies [49]. Notably, the probiotic
genus Lactobacillus also produces distinct EPSs, which are
structurally similar to those observed in bifidobacteria [50].
Recently, within an in vitro system (HT29-19A epithelial cell
line), the EPS from Lactobacillus acidophilus 5e2 was shown to
increase IL-8 expression and also TLR2 expression (we also
observe that B. breve UCC2003 induces IEC TLR2 expression),
and additionally upregulation of TLR2 was found to poten-
tially ‘sensitize’ epithelial cells to subsequent stimulation
with peptidoglycan (a TLR2 agonist) [51]. Furthermore, the
authors also observed a modest increase in TLR4 expression
after addition of EPS, but did not detect any significant modu-
lation of IL-8 responses after primingwith EPS and subsequent
addition of LPS, which may indicate less of a role for EPS–
TLR4 interactions [51]. From a more systemic perspective, in
the instance that Lactobacillus or indeed B. breve UCC2003
potentially translocate across the epithelial barrier, it could
by hypothesized they directly influence macrophage function.
Previous studies have shown that L. casei Shirota can dampen
down inflammatory macrophage responses, and L. rhamnosus
EPS has also been shown to modulate macrophage function
in vitro, but on this occasion induced proinflammatory
responses [52,53]. Ideally, we would test our B. breve strains
in TLR2 and/or TLR4 KO animals; unfortunately, previous
work has shown that these mice do not respond to LPS and
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further studies not possible. However, in studies using RNA-
scope, we found significant numbers of B. breve UCC2003
associated with the villi in colonized mice (electronic sup-
plementary material, figure S3), suggesting that direct
signalling interactions between the bacteria (possibly via EPS
and TLRs, and B. breve UCC2003 colonization increases TLR2
expression) and IECs may play an important role in modulat-
ing this response. These data, alongside our findings, suggest
that B. breve EPS may regulate cell shedding by acting as TLR
ligands via MyD88, leading to protective epithelial responses.
To probe these EPS–epithelial interactions further, we took
advantage of the bidirectional eps gene cluster in B. breve
UCC2003, which can express two genetically and importantly
chemically distinct surfaces EPSs [7]. All previous studies used
EPS1 (i.e. with B. breve UCC2003), but we also determined
responses following EPS2 (i.e. B. breve UCC2003-EPSInv) colo-
nization. Strikingly, and contrary to our expectations,we found
that this isogenic strain was unable to confer protection against
LPS-induced cell shedding (figure 5c,d). Importantly, EPSs are
composed of repeating mono- or oligosaccharides linked by
various glycosidic linkages, and the three-dimensional struc-
tures and other physiochemical features of EPSs can vary
widely [54]. The variability in chemical composition of these
two B. breve EPSs (previous work suggests the EPSs may
include glucose, galactose and/or the N-acetylated versions
of these two sugars in different ratios or composition [7])
could, in part, explain the different modulatory properties of
this molecule in relation to receptor-ligand binding, and
further highlights the issues with significant strain (or in this
case isogenic), variation in effects on host responses. Impor-
tantly, these different EPS-epithelium protective responses do
not appear to be linked to colonization ability as all strains
colonized mice at similar levels (electronic supplementary
material, figure S1). Previous limited studies have indicated
that specific chemical structures of EPSs such as PSA of
B. fragilis (comprised an unusual repeating tetrasaccharide
moiety, free carboxyl, phosphate and amino groups, that con-
tribute to its zwitterionic nature) are important for function
[46]. Additionally, in vitro studies on L. reuteri strains (DSM
17938 and L26 Biocenol) indicate both EPSs are high-molecu-
lar-weight D-glucan polysaccharides with differing spatial
conformations, which may relate to induction of different
cytokine responses. However, the direct chemical structures
involved in this modulation have yet to be defined [55].
Future challenges will include studies to fully chemically
characterize the different strains of ‘probiotic’ bacteria, as
evidently significant differences in response to small strain
variations (including variations in EPS expression and struc-
ture and also other MAMPS) may impact beneficial host
responses [56,57].
We have previously shown that EPS-positive B. breve
UCC2003 does not induce inflammatory host responses after
colonization, which we hypothesize is to the advantage of
the bacterium and host for maintaining efficient symbiosis
and homeostasis [7]. Interestingly, when we probed the down-
stream signalling transcriptional events after colonization and
LPS challenge, we determined that presence of EPS1 (i.e.
B. breve UCC2003) appeared to attenuate apoptosis-induced
signalling activation, in stark contrast to mice colonized with
the B. breve UCC2003-EPSdel strain, which had significantly
elevated apoptotic gene expression (figure 6; electronic sup-
plementary material, figure S5). Importantly, previous workhas demonstrated that activation of MyD88 can downregulate
several of these genes including Fas (CD95) [58]. Fas is a cell
surface receptor and member of the TNF superfamily, and
when bound by its ligand induces apoptosis through the
assembly of a multiprotein complex called DISC, which in
turn activates caspase 8 (i.e. extrinsic apoptosis pathway)
[59]. Further evidence of an EPS-specific mechanism attenuat-
ing epithelial apoptosis comes from the observation that Bad,
Cycs, casp4, Traf5 and Tnfr9 are upregulated in the intestinal
mucosa of mice colonized by B. breve UCC2003-del compared
with B. breve UCC2003-colonized mice. Bad is a pro-apoptotic
(BH3-only) member of the bcl-2 family that antagonizes the
anti-apoptosis proteins bcl-2, bcl-xl and bcl-2, allowing acti-
vation of bax/bak oligomers and release of cytochrome c
from the mitochondria. Within the same pathway, Cycs
encodes the haem protein cytochrome c, which forms a multi-
protein complex called the apoptosome, which activates a
cascade of caspases which cause apoptotic cell death [60].
Traf5 is a scaffold protein that forms a multiprotein complex
with TRAF2, RIP1 and the TNF receptor, and can potentially
mediate the activation of apoptosis and NF-kB [61]. We have
previously shown that NF-kB1 inhibits LPS-induced apoptotic
cell shedding, whereas NF-kB2 stimulates apoptotic cell shed-
ding [22]. TNFRF9 (CD137) is expressed onT cells and has been
reported to enhance their cytolytic activity [62]. These data
strongly suggest that, mechanistically, B. breve UCC2003, via
EPS, may block intrinsic and extrinsic apoptosis signalling (via
activation ofMyD88) during inflammation to protect epithelial
cells under highly apoptotic conditions.
In summary, we have demonstrated that certain bifidobac-
teria (i.e. B. breve UCC2003) are able to protect against
pathologic cell shedding induced by IP injection of LPS, and
that this protection appears to be independent of TNF-a pro-
duction by resident tissue macrophages. Using wild-type and
mutant B. breve, we have demonstrated that a specific EPS is
able to confer this protection and, using knockout mice, have
shown that this protection appears contingent on functional
(MyD88) signalling downstream of the epithelial TLR family
members and modulation of pro-apoptotic gene pathways.
Understanding how health-promoting species of bacteria such
as the Bifidobacterium genus interact with the intestinal epi-
thelium and how these species confer their protective effects
may drive progress towards understanding how pathologic
cell shedding in IBD patients is linked to changes in the intesti-
nal microbiota and how intervention strategies could positively
impact disease progression. Future human studies could be
considered to address issues ofmicrobial dysbiosis, the relation-
ship to the cell shedding response, to what extent microbial
dysbiosis is linked to periods of remission and relapse in such
patients, and how bifidobacterial supplementation could be
used to reduce relapse in IBD patients.
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